Sofosbuvir and velpatasvir

(Epclusa®)

Epclusa®

Drug updated on 4/26/2024

Dosage FormTablet (oral; sofosbuvir/velpatasvir: 400 mg/100 mg, 200 mg/50 mg); Pellet (oral; sofosbuvir/velpatasvir: 200 mg/50 mg, 150 mg/37.5 mg)
Drug ClassHCV NS5A inhibitors and HCV nucleotide analog NS5B polymerase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
  • For the treatment of adult and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection with decompensated cirrhosis in combination with ribavirin.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Sofosbuvir and velpatasvir (Epclusa) is indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. It can also be used in combination with ribavirin for treating those same patients who have decompensated cirrhosis.
  • The information about this drug was derived from a total of eight systematic reviews/meta-analyses documents that provided comprehensive understanding of its efficacy and safety compared to other treatments for Hepatitis C Virus (HCV) infection across diverse populations.
  • In terms of population type considerations, Epclusa showed high effectiveness in adolescents with SVR12 rates of around 83% to 95%, slightly lower than glecaprevir/pibrentasvir (GLE/PIB), and sofosbuvir/daclatasvir (SOF/DCV). However, it had good tolerability as adverse events increased only marginally among younger ages.
  • For subgroup considerations such as Decompensated Cirrhosis Patients, SOF/VEL achieved higher sustained virologic response (SVR) rates (91%) compared to SOF/Ledipasvir and SOF/Daclatasvir variants. This indicates superior efficacy within this subgroup while maintaining a safety profile when not combined with Ribavarin, which tends to increase adverse effects.
  • Compared to other drugs used in treating chronic HCV infections like GLE/PIB & SOF/DAC, Epclusa consistently shows high SVR12 rates across various genotypes, including traditionally hard-to-treat ones like Genotype 3 (GT3).
  • Sofosbuvir/Velpatasvir has been shown to be effective even amongst patient demographics considered challenging, such as those suffering from End Stage Renal Disease (ESRD) and children, making it a versatile option for treating HCV across diverse patient subgroups.

Product Monograph / Prescribing Information

Document TitleYearSource
Epclusa (sofosbuvir and velpatasvir) Prescribing Information.2022Gilead Sciences, Inc., Foster City, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines